Cargando…

Reclassification of coronary artery disease risk using genetic risk score among subjects with borderline or intermediate clinical risk

Detalles Bibliográficos
Autores principales:	Ahmed, Razina A., Shi, Zhuqing, Rifkin, Andrew S., Wei, Jun, Lilly Zheng, S., Helfand, Brian T., Hulick, Peter J., Woo, Jonathan S.H., Qamar, Arman, Davidson, David J., Billings, Liana K., Xu, Jianfeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579501/ https://www.ncbi.nlm.nih.gov/pubmed/36275420 http://dx.doi.org/10.1016/j.ijcha.2022.101136

Ejemplares similares

Assessing the performance of genetic risk score for stratifying risk of post-sepsis cardiovascular complications
por: McElligott, Brian, et al.
Publicado: (2023)

Risk assessment of venous thromboembolism in inflammatory bowel disease by inherited risk in a population-based incident cohort
por: Rifkin, Andrew S, et al.
Publicado: (2023)

Systematic review of reported association studies of monogenic genes and bladder cancer risk and confirmation analysis in a large population cohort
por: Mian, Abrar, et al.
Publicado: (2022)

Reliability of Ancestry-specific Prostate Cancer Genetic Risk Score in Four Racial and Ethnic Populations
por: Shi, Zhuqing, et al.
Publicado: (2022)

Association of Sickle Cell Trait with Risk and Mortality of COVID-19: Results from the United Kingdom Biobank
por: Resurreccion, W. Kyle, et al.
Publicado: (2021)

Germline HOXB13 G84E mutation carriers and risk to twenty common types of cancer: results from the UK Biobank
por: Wei, Jun, et al.
Publicado: (2020)

Assessing the clinical utility of genetic risk scores for targeted cancer screening
por: Conran, Carly A., et al.
Publicado: (2021)

Single-Nucleotide Polymorphism–Based Genetic Risk Score and Patient Age at Prostate Cancer Diagnosis
por: Na, Rong, et al.
Publicado: (2019)

Risk categorization for calculating net reclassification improvement
por: Takahara, Mitsuyoshi, et al.
Publicado: (2013)

Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes
por: Liapis, Konstantinos, et al.
Publicado: (2021)

Coronary artery disease risk reclassification by a new acoustic-based score
por: Schmidt, S. E., et al.
Publicado: (2019)

Validation of a prostate cancer polygenic risk score
por: Black, Mary H., et al.
Publicado: (2020)

Association of sickle cell trait with adverse pregnancy outcomes in a population‐based cohort
por: Hulsizer, Joseph, et al.
Publicado: (2023)

Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trial
por: Albers, Peter, et al.
Publicado: (2020)

Reclassification of genetic-based risk predictions as GWAS data accumulate
por: Krier, Joel, et al.
Publicado: (2016)

Methylation-based reclassification and risk stratification of skull-base chordomas
por: Huo, Xulei, et al.
Publicado: (2022)

Clinical validity and utility of genetic risk scores in prostate cancer
por: Helfand, Brian T, et al.
Publicado: (2016)

Data on coronary artery calcium score performance and cardiovascular risk reclassification across gender and ethnicities
por: Fudim, Marat, et al.
Publicado: (2016)

Computed tomography calcium scoring association and reclassification of clinical cardiovascular risk in asymptomatic Mexican patients
por: Vázquez Mézquita, Aldo Javier, et al.
Publicado: (2020)

HPV‐related methylation‐based reclassification and risk stratification of cervical cancer
por: Yang, Si, et al.
Publicado: (2020)

A comparison of genetic risk score with family history for estimating prostate cancer risk
por: Helfand, Brian T
Publicado: (2016)

In Search of the Ideal Risk Score in Sepsis
por: Topeli, Arzu, et al.
Publicado: (2020)

Vasohibin-1 as a novel microenvironmental biomarker for patient risk reclassification in low-risk prostate cancer
por: Kobayashi, Hiroaki, et al.
Publicado: (2017)

Risk reclassification analysis investigating the added value of fatigue to sickness absence predictions
por: Roelen, Corné A. M., et al.
Publicado: (2015)

Disease activity influences the reclassification of rheumatoid arthritis into very high cardiovascular risk
por: Ferraz-Amaro, Iván, et al.
Publicado: (2021)

Initial Triple Combination Therapy for Intermediate-and High-Risk Pulmonary Arterial Hypertension: Standard of Care or Still Too Soon to Tell?
por: Jin, Qi, et al.
Publicado: (2021)

Gemtuzumab ozogamicin plus standard induction chemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia
por: Awada, Hassan, et al.
Publicado: (2023)

Borderline Thrombocytopenia or Mild Idiopathic Thrombocytopenic Purpura?
por: Zimmer, Jacques, et al.
Publicado: (2006)

Ultrasound risk marker variability in symptomatic carotid plaque: impact on risk reclassification and association with temporal variation pattern
por: Stenudd, Isak, et al.
Publicado: (2020)

Reclassification of Cardiovascular Risk Based on the Presence of Carotid Plaque Regarding Statin Eligibility in Low to Moderate Risk Patients
por: Park, Chan Seok
Publicado: (2022)

Systematic evaluation of cancer‐specific genetic risk score for 11 types of cancer in The Cancer Genome Atlas and Electronic Medical Records and Genomics cohorts
por: Shi, Zhuqing, et al.
Publicado: (2019)

Race-specific genetic risk score is more accurate than nonrace-specific genetic risk score for predicting prostate cancer and high-grade diseases
por: Na, Rong, et al.
Publicado: (2016)

Comment on: Validation of the Liver Transplant Risk Score in Europe
por: Suresan, Srutti, et al.
Publicado: (2022)

Comment on: ‘Development of PancRISK, a urine biomarker-based risk score for stratified screening of pancreatic cancer patients’
por: De Marco, Margot, et al.
Publicado: (2020)

The clinical utility of polygenic risk scores for chronic lymphocytic leukemia
por: Sud, Amit, et al.
Publicado: (2021)

Umbilicated Papules as a Rare Manifestation of Borderline Lepromatous Leprosy
por: Kumar, Piyush, et al.
Publicado: (2021)

Response to the comment on “Development of PancRISK, a urine biomarker-based risk score for stratified screening of pancreatic cancer patients”
por: Blyuss, Oleg, et al.
Publicado: (2020)

The 17-gene Genomic Prostate Score assay as a predictor of biochemical recurrence in men with intermediate and high-risk prostate cancer
por: Helfand, Brian T., et al.
Publicado: (2022)

Statin Use and Eligibility for Primary Prevention of Atherosclerotic Cardiovascular Disease Among Adults at Borderline or Intermediate Risk in the United States
por: Hammond, Michael M., et al.
Publicado: (2023)

Cardiovascular Event Prediction and Risk Reclassification by Coronary, Aortic, and Valvular Calcification in the Framingham Heart Study
por: Hoffmann, Udo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_49jcnmm3b923r0caou40br5f4c